- Home
- CHA vs BIO Comparison
CHA vs BIO Comparison
Compare CHA & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHA
- BIO
- Stock Information
- Founded
- CHA 2017
- BIO 1952
- Country
- CHA China
- BIO United States
- Employees
- CHA N/A
- BIO N/A
- Industry
- CHA
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- CHA
- BIO Industrials
- Exchange
- CHA NYSE
- BIO Nasdaq
- Market Cap
- CHA 6.6B
- BIO 6.7B
- IPO Year
- CHA 2025
- BIO N/A
- Fundamental
- Price
- CHA $32.00
- BIO $239.02
- Analyst Decision
- CHA
- BIO Strong Buy
- Analyst Count
- CHA 0
- BIO 4
- Target Price
- CHA N/A
- BIO $330.50
- AVG Volume (30 Days)
- CHA 2.9M
- BIO 314.3K
- Earning Date
- CHA 01-01-0001
- BIO 05-01-2025
- Dividend Yield
- CHA N/A
- BIO N/A
- EPS Growth
- CHA 186.29
- BIO N/A
- EPS
- CHA 1.95
- BIO N/A
- Revenue
- CHA $1,699,604,333.00
- BIO $2,541,100,000.00
- Revenue This Year
- CHA N/A
- BIO $0.84
- Revenue Next Year
- CHA N/A
- BIO $4.64
- P/E Ratio
- CHA $16.64
- BIO N/A
- Revenue Growth
- CHA 167.35
- BIO N/A
- 52 Week Low
- CHA $29.00
- BIO $215.38
- 52 Week High
- CHA $41.80
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- CHA N/A
- BIO 47.23
- Support Level
- CHA N/A
- BIO $228.91
- Resistance Level
- CHA N/A
- BIO $243.75
- Average True Range (ATR)
- CHA 0.00
- BIO 9.67
- MACD
- CHA 0.00
- BIO 0.36
- Stochastic Oscillator
- CHA 0.00
- BIO 32.51
About CHA CHAGEE HOLDINGS LTD SPON ADS EACH R SPON ADS EACH REP 1 CL A
Chagee Holdings Ltd is a premium tea drinks brand. It is engaged in the sales of freshly-made tea drinks, related raw materials, packaging, teahouse equipment and other supplies in China.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.